SEC Tracker
Get the app

Supernus Pharmaceuticals

Jack A. Khattar (President, CEO) reported 2,216,451 SUPN

Form
4
Filed
Importance
Routine
  1. 1,258,351 common shares disposed of
  2. 958,100 common shares held indirectly via KBT Trust
  3. 400,000 restricted stock units (shares paid out over time) converted
  4. 250,000 employee stock options converted

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Supernus Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Sarepta Therapeutics SRPT public float $1.7B, Jun 30, 2025
  2. Amicus Therapeutics FOLD public float $1.7B, Jun 30, 2025
  3. Ocular Therapeutix OCUL public float $1.6B, Jun 30, 2025
  4. Ligand Pharmaceuticals LGND public float $1.6B, Jun 30, 2025
  5. Apellis Pharmaceuticals APLS public float $1.8B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.